Fig. 1From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysisPatient flow. HBV, hepatitis B virus; HCC, hepatocellular carcinomaBack to article page